4.6
CiteScore
2.2
Impact Factor
- ISSN 1674-8301
- CN 32-1810/R
4.6
2.2
| Citation: |
Xinlu Chai, Yuting Meng, Wei Ge, Juan Wang, Fei Li, Xue Jun Wang, Xuerong Wang. A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells[J]. The Journal of Biomedical Research, 2023, 37(5): 355-366. DOI: 10.7555/JBR.37.20230022
|
In the present study, we introduced the H2O2-sensitive thiazolidinone moiety at the 4th amino group of gemcitabine (GEM) to synthesize a new target compound named GEM-ZZQ, and then we confirmed its chemical structure by nuclear magnetic resonance spectroscopy. We further confirmed that GEM-ZZQ had a good chemical stability in different pH solutions in vitro and that it could be activated by H2O2 to release GEM. Pharmacodynamic studies revealed that the growth inhibition of human normal epithelial cells was weaker by GEM-ZZQ than by GEM treatment and that the inhibition of various lung cancer cell lines by GEM-ZZQ was similar to that of GEM. For the lung cancer cell lines that are resistant to the epidermal growth factor receptor (EGFR)-targeting inhibitor osimertinib, GEM-ZZQ showed less growth inhibition than GEM; however, GEM-ZZQ in combination with cisplatin showed better synergistic effects than GEM in the low-dose groups. In summary, we provided a new anti-cancer compound GEM-ZZQ for treating lung cancer by modifying the GEM structure.
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81972763 and 81473241).
We acknowledge and appreciate our colleagues for their valuable efforts and comments on this paper.
CLC number: R966, Document code: A
The authors reported no conflict of interests.
| [1] |
Heinemann V, Xu Y, Chubb S, et al. Cellular elimination of 2', 2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation[J]. Cancer Res, 1992, 52(3): 533–539. https://typeset.io/papers/cellular-elimination-of-2-2-difluorodeoxycytidine-5-31nzxo1c13
|
| [2] |
Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances[J]. Expert Opin Investig Drugs, 2006, 15(11): 1395–1410. doi: 10.1517/13543784.15.11.1395
|
| [3] |
Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?[J]. Br J Cancer, 2007, 97(2): 145–151. doi: 10.1038/sj.bjc.6603860
|
| [4] |
Plunkett W, Huang P, Xu Y, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation[J]. Semin Oncol, 1995, 22(4 Suppl 11): 3–10. https://pubmed.ncbi.nlm.nih.gov/7481842/
|
| [5] |
Immordino ML, Brusa P, Rocco F, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs[J]. J Controlled Release, 2004, 100(3): 331–346. doi: 10.1016/j.jconrel.2004.09.001
|
| [6] |
Albert A. Chemical aspects of selective toxicity[J]. Nature, 1958, 182(4633): 421–423. doi: 10.1038/182421a0
|
| [7] |
Kapacee ZA, Knox JJ, Palmer D, et al. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials[J]. Med Oncol, 2020, 37(7): 61. doi: 10.1007/s12032-020-01386-6
|
| [8] |
Huttunen KM, Rautio J. Prodrugs - an efficient way to breach delivery and targeting barriers[J]. Curr Top Med Chem, 2011, 11(18): 2265–2287. doi: 10.2174/156802611797183230
|
| [9] |
Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency[J]. Adv Drug Deliv Rev, 2011, 63(8): 659–670. doi: 10.1016/j.addr.2011.02.002
|
| [10] |
Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs[J]. J Med Chem, 2004, 47(10): 2393–2404. doi: 10.1021/jm0303812
|
| [11] |
Kumar R, Han J, Lim HJ, et al. Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: in vivo imaging and precise cancer treatment[J]. J Am Chem Soc, 2014, 136(51): 17836–17843. doi: 10.1021/ja510421q
|
| [12] |
Zhou J, Nie R, Yin Y, et al. Protective effect of natural antioxidants on reducing cisplatin-induced nephrotoxicity[J]. Dis Markers, 2022, 2022: 1612348. doi: 10.1155/2022/1612348
|
| [13] |
Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells[J]. Cancer Res, 1991, 51(3): 794–798. https://pubmed.ncbi.nlm.nih.gov/1846317/
|
| [14] |
Xie X, Yang X, Wu T, et al. Rational design of an α-ketoamide-based near-infrared fluorescent probe specific for hydrogen peroxide in living systems[J]. Anal Chem, 2016, 88(16): 8019–8025. doi: 10.1021/acs.analchem.6b01256
|
| [15] |
Zhou X, Sun T, Meng Y, et al. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells[J]. Oncol Rep, 2021, 45(5): 70. doi: 10.3892/or.2021.8021
|
| [16] |
Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation[J]. Cancer Res, 2008, 68(18): 7409–7418. doi: 10.1158/0008-5472.CAN-08-1522
|
| [17] |
Xu K, Sun G, Li M, et al. Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small cell lung carcinoma[J]. Mol Cancer Ther, 2019, 18(11): 2085–2096. doi: 10.1158/1535-7163.MCT-18-1181
|
| [18] |
Chou T. The combination index (CI < 1) as the definition of synergism and of synergy claims[J]. Synergy, 2018, 7: 49–50. doi: 10.1016/j.synres.2018.04.001
|
| [19] |
Pereira M, Vale N. Repurposing alone and in combination of the antiviral saquinavir with 5-fluorouracil in prostate and lung cancer cells[J]. Int J Mol Sci, 2022, 23(20): 12240. doi: 10.3390/ijms232012240
|
| [20] |
Moloney JN, Cotter TG. ROS signalling in the biology of cancer[J]. Semin Cell Dev Biol, 2018, 80: 50–64. doi: 10.1016/j.semcdb.2017.05.023
|
| [21] |
Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154–162. doi: 10.1097/JTO.0000000000000033
|
| [22] |
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer[J]. Semin Cancer Biol, 2020, 61: 167–179. doi: 10.1016/j.semcancer.2019.09.015
|
| [23] |
Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725–737. doi: 10.1038/s41416-019-0573-8
|
| [24] |
Gorden KJ, Mesbah P, Kolesar JM. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC[J]. J Oncol Pharm Pract, 2012, 18(2): 245–249. doi: 10.1177/1078155211408373
|
| [25] |
Zhang K, Zhang Y, Lei H, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer[J]. Sci Transl Med, 2021, 13(614): eabg6428. doi: 10.1126/scitranslmed.abg6428
|
| [26] |
Hamai K, Fujitaka K, Kitaguchi S, et al. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study[J]. Anticancer Drugs, 2021, 32(7): 767–772. https://pubmed.ncbi.nlm.nih.gov/33967202/
|
| [27] |
Boonsong T, Usaha S, Nakwan N, et al. Survival analysis and clinical outcomes between paclitaxel and carboplatin versus carboplatin and gemcitabine in patients with advanced-stage non-small-cell lung cancer: a single-center cohort study[J]. Asian Pac J Cancer Prev, 2022, 23(10): 3371–3378. doi: 10.31557/APJCP.2022.23.10.3371
|
| [28] |
De Mello RA, Neves NM, Tadokoro H, et al. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives[J]. J Clin Med, 2020, 9(11): 3543. doi: 10.3390/jcm9113543
|
| [29] |
Moysan E, Bastiat G, Benoit JP. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications[J]. Mol Pharm, 2013, 10(2): 430–444. doi: 10.1021/mp300370t
|
| [1] | Liting Lv, Xin Hua, Jiaxin Liu, Sutong Zhan, Qianqian Zhang, Xiao Liang, Jian Feng, Yong Song. Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240045 |
| [2] | Sahil Khurana, Ajay Pal Singh, Ashok Kumar, Rajeev Nema. Prognostic value of AKT isoforms in non-small cell lung adenocarcinoma[J]. The Journal of Biomedical Research, 2023, 37(3): 225-228. DOI: 10.7555/JBR.36.20220138 |
| [3] | Wang Jing, He Xuezhi, Lu Xiyi, Amin Karim Muhammad, Miao Dengshun, Zhang Erbao. A novel long non-coding RNA NFIA-AS1 is down-regulated in gastric cancer and inhibits proliferation of gastric cancer cells[J]. The Journal of Biomedical Research, 2019, 33(6): 371-381. DOI: 10.7555/JBR.33.20190015 |
| [4] | Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065 |
| [5] | Yong Ji, Mingfeng Zheng, Shugao Ye, Jingyu Chen, Yijiang Chen. PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer[J]. The Journal of Biomedical Research, 2014, 28(6): 462-467. DOI: 10.7555/JBR.27.20130084 |
| [6] | Keping Xu, Zhi Zhang, Jianqiang Zhao, Jianfeng Huang, Rong Yin, Lin Xu. Partial removal of the pulmonary artery in video-assisted thoracic surgery for non-small cell lung cancer[J]. The Journal of Biomedical Research, 2013, 27(4): 310-317. DOI: 10.7555/JBR.27.20120066 |
| [7] | Songyu Cao, Cheng Wang, Xinen Huang, Juncheng Dai, Lingmin Hu, Yao Liu, Jiaping Chen, Hongxia Ma, Guangfu Jin, Zhibin Hu, Lin Xu, Hongbing Shen. Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese[J]. The Journal of Biomedical Research, 2013, 27(3): 231-238. DOI: 10.7555/JBR.27.20130014 |
| [8] | Wenze Sun, Liping Song, Ting Ai, Yingbing Zhang, Ying Gao, Jie Cui. Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer[J]. The Journal of Biomedical Research, 2013, 27(3): 220-230. DOI: 10.7555/JBR.27.20130004 |
| [9] | Li Sun, Xiaoli Fan. Expression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significance[J]. The Journal of Biomedical Research, 2013, 27(3): 202-207. DOI: 10.7555/JBR.27.20120019 |
| [10] | Qi Zheng, Yu Yao, Kejun Nan. Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases[J]. The Journal of Biomedical Research, 2012, 26(3): 159-164. DOI: 10.7555/JBR.26.20110106 |
Figures(6) / Tables(4)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
Authors and Reviewers
DownLoad: